Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland

Reports on real-world experience on efficacy of bezlotoxumab (BEZ) has been lacking thus far. We retrospectively studied the efficacy and safety of BEZ in preventing the recurrence of Clostridium difficile infection (CDI) in five university hospitals in Finland. Seventy-three percent of our 46 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Oksi, Jarmo, Aalto, A., Säilä, P., Partanen, T., Anttila, V.-J., Mattila, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778539/
https://www.ncbi.nlm.nih.gov/pubmed/31359254
http://dx.doi.org/10.1007/s10096-019-03630-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778539/
https://www.ncbi.nlm.nih.gov/pubmed/31359254
http://dx.doi.org/10.1007/s10096-019-03630-y

Ejemplares similares